Evinacumab as an adjunct to lipid apheresis in an infant with homozygous familial hypercholesterolemia
Journal of Pediatric Endocrinology and Metabolism · 2025
DOI: 10.1515/jpem-2024-0505 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Pediatric Endocrinology and Metabolism, 2025. Verfasst von Christian Stirnkorb und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Nephrology, Olga-Hospital, Clinic of Stuttgart, Stuttgart, Germany. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, Blood Component Removal, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Investigation of the efficacy of the angiopoietin-like protein 3 (ANGPTL3) antibody evinacumab in a four-year-old infant with homozygous familial hypercholesterolemia (HoFH) as an adjunct to lipid apheresis. Case presentation A two-year-old boy was found to have xanthomas of the Achilles tendon and LDL cholesterol levels around 900 mg/dL. HoHF was subsequently confirmed by molecular genetics. At the age of three, lipid apheresis was started twice a week. At the age of four, a four-weekly infusion of evinacumab was started. This resulted in a 67 % reduction in LDL cholesterol before apheresis, allowing the frequency of apheresis to be reduced to once a week. The mean LDL concentration fell by a further 37 % despite the reduction in apheresis. With the addition of ezetimibe, the mean LDL concentration was reduced to below 115 mg/dL.
Conclusions
The administration of evinacumab can significantly lower the concentration of LDL cholesterol in infants and thus reduce the frequency of lipid apheresis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Nephrology, Olga-Hospital, Clinic of Stuttgart, Stuttgart, Germany.
- Medizinische Genetik Mainz, Limbach Genetics, Mainz, Germany.
ORCID-Profile: Martin Bald
Zitieren
APA
Stirnkorb, C., Ney, V., Bergmann, C., & Bald, M. (2025). Evinacumab as an adjunct to lipid apheresis in an infant with homozygous familial hypercholesterolemia. Journal of Pediatric Endocrinology and Metabolism. https://doi.org/10.1515/jpem-2024-0505
Vancouver
Stirnkorb C, Ney V, Bergmann C, Bald M. Evinacumab as an adjunct to lipid apheresis in an infant with homozygous familial hypercholesterolemia. Journal of Pediatric Endocrinology and Metabolism. 2025. doi:10.1515/jpem-2024-0505
BibTeX
@article{Stirnkorb2025,
author = {Stirnkorb, Christian and Ney, Verena and Bergmann, Carsten and Bald, Martin},
title = {Evinacumab as an adjunct to lipid apheresis in an infant with homozygous familial hypercholesterolemia},
journal = {Journal of Pediatric Endocrinology and Metabolism},
year = {2025},
doi = {10.1515/jpem-2024-0505}
}
EUVIMED